Several studies have now identified that MAPK pathway reactivation constitutes a mechanism of therapy resistance in BRAF V600E mutated colorectal carcinomas that are treated with Vemurafenib [1], [20], [21]. The gene discussed is BRAF; the disease is colorectal carcinoma.